1 / 38

Constipation

Constipation. Cengiz Pata Gastroenterology Department Yeditepe University. Constipation. Epidemiology of Constipation Objectives of self-treatment Nondrug Measures OTC medications for the relief of constipation. Constipation. Signs and Symptoms include:

mborrelli
Download Presentation

Constipation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Constipation Cengiz Pata Gastroenterology DepartmentYeditepe University

  2. Constipation • Epidemiology of Constipation • Objectives of self-treatment • Nondrug Measures • OTC medications for the relief of constipation

  3. Constipation Signs and Symptoms include: • A decrease in the frequency of fecal elimination • Difficult passage of dry hard stools • Straining to have stool

  4. Constipation Common medications that can induceconstipation are: • Narcotic analgesics • Calcium-or aluminum containing antacids • Drugs with anticholinergic activity • Tricyclic antidepressants • Certain calcium channel blockers: ex. Verapamil

  5. Constipation Can be induced by one of the following diseases: • Hypothoroidism • Megacolon • Stricture • Diabetes Mellitus • Irritable Bowel Syndrome

  6. A.Ş.K. Ağrı Şişkinlik Kabızlık

  7. Irritable bowel syndrome (IBS) • IBS is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit, and with features of disordered defecation • 10-20% adults in world, female predominant • Come and go over time, overlap with other FGID • Poor QoL, high heath care costs Longstreth GF, et al. Gastroenterology 2006;130:1480-91.

  8. Enteric nervous system (ENS)

  9. Brain imaging in rectal stimulation (fMR) • Normal visceral sensation: • 1. Gender difference,  ACC & PFC in females • 2. Common FGID in females? Grundy D, et al. Gastroenterology 2006;130:1391-1411.

  10. VS IBS in females

  11. Sex hormones or gender impacts on brain-gut axis • Animals • Low threshold for visceromotor response in rat proestrus vs estrus phase •  potency of opiates to  visceromotor response in male rats • Modulation of response in afferent neurons of male GP • Drugs: estrogen/progesteron on P-450 system • CYP3A4: women clearing drugs quickly • Humans • Slow GE in women • Women experience greater pain to most stimuli • Different areas of brain activation: males vs females • Different polymorphism of 5-HT transporter promoter: males vs females Ouyang A, et al. Am J Gastroenterol 2006;101:S602-9.

  12. Diagnostic criteria for IBS, C1 • Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following: • Improvement with defecation • Onset associated with a change in frequency of stool • Onset associated with a change in form (appearance) of stool • Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis • Discomfort: uncomfortable sensation not described as pain Longstreth GF, et al. Gastroenterology 2006;130:1480-91.

  13. Diagnostic criteria for IBS • Organik sebepleri dışla • Roma II criteria • Son 12 ayda en az ≥12 hafta olan abdominal ağrı ve huzursuzluk ve dışkılama alışkanlığında değişiklik olacak • Ve aşağıdakilerden en az ikisi eşlik edecek • defakasyonla rahatlama • dışkının kıvamında değişiklik • dışkının şeklinde değişiklik Aşağıdaki semptomların bulunması şart değildir, fakat bunlardan ne kadar çoğu mevcutsa, tanı o kadar kesinleşir: • Anormal dışkılama sıklığı (>3/günveya <3/hafta) • Anormal dışkı şekli • Anormal dışkı pasajı • Mukus pasajı • Şişkinlik veya abdominal distansiyon hissi

  14. Sub-typing IBS by predominant stool pattern • Subtype (absent use of antidiarrheals or laxatives) • IBS-C (IBS with constipation): hard or lumpy stools >25% and loose (mushy) or watery stools <25% of BMs • IBS-D (IBS with diarrhea): loose (mushy) or watery stools >25% and hard or lumpy stool <25% of BMs • IBS-M (mixed IBS): hard or lump stools >25% and loose (mushy) or watery stools > 25% of BMs • IBS-U (unsubtyped IBS): insufficient abnormality of stool consistency to meet criteria for IBS-C, D, or M • Stool form:Bristol scale Longstreth GF, et al. Gastroenterology 2006;130:1480-91.

  15. Alarm symptoms in IBS diagnosis • Age of onset over 50 yrs • Progressive or very severe non-fluctuating symptoms • Nocturnal symptoms waking from sleep • Persisted diarrhea, recurrent vomiting • Rectal bleeding, anemia • Unexplained BW loss • Family history of colon cancer • Fever • Abnormal physical examinations Talley NJ, et al. Lancet 2002;360:555-564.

  16. Patient Assessment • Obtain lifestyle and medical history before making any recommendations • Determine the reason for use of a laxative product 1. To relieve constipation 2. To evacuate the bowel prior to an upcoming radiologic or endoscopic examination • Inquire about the patient’s current and past use of laxative products

  17. Refer When…… • Symptoms have persisted for more than 2 weeks • Have recurred after previous dietary or lifestyle changes or laxative use • Patients who admit to blood in the stool

  18. Objectives for Self Treatment To relieve constipation and restore “normal” bowel functioning using: • Dietary and Lifestyle measures • Using OTC medications for the relief of constipation

  19. Nondrug Measuresinclude • High fiber diet: foods high in wheat grains, oats, or fruits & vegetables • Adequate fluid intake • Exercise • Avoid foods that cause constipation: processed cheeses & concentrated sweets

  20. Non Prescription Medications Types of laxatives: • Bulk Forming Laxatives • Emollient • Lubricant • Saline • Hyperosmotic • Stimulant

  21. Bulk Forming Laxatives • Derived from agar, or psyllium seed • Synthetic examples used today are methylcellulose & carboxymethyl cellulose sodium • Dissolve in the intestinal fluid, thus creating emollient gels that increase passage of the intestinal contents • Stimulate peristalsis • No systemic absorption

  22. Bulk Forming Laxatives • Onset of action is 12-24hrs • Resemble the physiologic mechanism in promoting evacuation • Are the FIRST choice of therapy for constipation • Examples are: Citrucel powder, Metamucil, Mitrolan Chewable Tablets

  23. Bulk Forming Laxatives • Use caution in patients that are younger than 6 yrs of age • Avoid in pts with intestinal ulcerations, stenosis • Interact with anticoagulants, digitalis glycosides, and salisylates • Not used for a fast clearing effect before a diagnostic procedure

  24. Emollient Laxatives • Are anionic surfactants that eventually lead to the softening of the stool • Are systemically absorbed (solid) • Onset of action (oral) 24-72hrs • Major use is as a stool softener, & to prevent constipation and maintain regularity • Example : Docusate sodium • Avoid in pts with who have nausea, vomiting, or undetermined abdominal pain

  25. Lubricant Laxatives • Prevent colonic absorption of fecal water, thus soften the stool • Are minimally absorbed • Onset of action (oral) 6-8 hrs, (rectal) 5-15 min • Avoid prolonged use • Can cause malabsorption of fat-soluble vitamins • Example: Mineral oil ( only)

  26. Saline Laxatives • Nonabsorbable cations & anions that draw water into intestine causing an increase in intraluminal pressure, which stimulates intestinal motility • Are systemically absorbed • Onset of action (oral)30min-3 hrs,(rectal) 2-5min • Used ONLY when fast clearance of the bowel is required • Ex:Citroma, Fleet Ready-to-Use Enema • Avoid in pts with CHF, ileostomy, renal function impairment, or younger than 6 yrs old

  27. Hyperosmotic Laxatives • Combine an osmotic effect with local effect of sodium sterate, which draws water into rectumbowel movement • Onset of action (rectal) 30 min • Used in suppository form • Minimal side effects • Example: Glycerin suppositories (only) • Avoid in pts with rectal irritation

  28. Stimulant Laxatives • Come from 2 classes: anthraquinone (ex:senna) & diphenylmethane ( bisacodyl) • Increase the propulsive peristaltic activity of the intestine by local irritation of the mucosa which leads to increased motility • Onset of action senna (PO) 8-12 hrs • For Bisacodyl: oral/rectal 15-60min, • Are systemically absorbed • Major use: for thorough evacuation of the bowel prior to GI surgery or examination

  29. Stimulant Laxatives • Examples: Sennakot, Sennakot S (with sodium docusate), Exlax, Dulcolax • Interact with H1 blockers, antacids if administered within 1 hr • Avoid in pregnancy • Pts who are breast feeding & taking senna laxative have reported a brown discoloration of breast milk • Adverse effects with regular use are severe cramping, electrolyte & fluid deficiencies, metabolic acidosis/alkalosis, and others

  30. Patient Counseling • Laxative use to treat constipation should be only on a temporary measure • If laxatives are not effective after 1 week, a physician should be consulted

More Related